摘要:
A compound represented by the general formula (I):
wherein R 1 is
wherein R 26 and R 28 are each independently lower alkyloxy and the like; n 1 is an integer of 0 to 3; Z is a optionally substituted C1-C5 alkynylene which may be interrupted with a substituent selected from Substituent group a and the like; A is a group represented by the formula:
wherein R 6 and R 7 are each independently lower alkyl and the like; m and n are each independently 0, 1, or 2; R 2 is a hydrogen atom and the like; R 3 is optionally substituted lower alkyl and the like; R 4 is a hydrogen atom; or R 3 and R 4 may be taken together with an adjacent carbon atom to from a ring; R 5 is hydroxyl and the like, or an optically active isomer, a pharmaceutically acceptable salt or a solvate thereof.
摘要翻译:由通式(I)表示的化合物:其中R 1是其中R 26和R 28各自独立地为低级烷氧基等; n 1为0〜3的整数, Z是可以被选自取代基组a等的取代基中断的任选取代的C 1 -C 5亚炔基; A是由下式表示的基团:其中R 6和R 7各自独立地为低级烷基等; m和n各自独立地为0,1或2; R 2是氢原子等; R 3是任选取代的低级烷基等; R 4是氢原子; 或R 3和R 4可以与相邻的碳原子一起与环一起取代; R 5是羟基等,或光学活性异构体,其药学上可接受的盐或溶剂化物。
摘要:
The present invention provides novel compounds having a P2X 3 and/or P2X 2 / 3 receptor antagonistic effect. A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I):
wherein R h and R j are taken together to form a bond; R a and R b and/or R d and R e are taken together to form oxo or the like; R c is hydrogen, substituted or unsubstituted alkyl or the like; R f is -(CR 4a R 4b )n-R 2 ; R 4a and R 4b are hydrogen, substituted or unsubstituted alkyl or the like; R 2 is substituted or unsubstituted cycloalkyl or the like; n is an integer of 1 to 4; -R g is -X-R 3 ; -X- is -O-, -S- or the like; R 3 is substituted or unsubstituted cycloalkyl or the like, or its pharmaceutically acceptable salt or a solvate thereof.
摘要翻译:本发明提供具有P2X 3和/或P2X 2/3受体拮抗作用的新型化合物。 一种具有镇痛作用或排尿障碍改善作用的药物组合物,其包含式(I)化合物:其中R h和R j一起形成键; R a和R b和/或R d和R e一起形成氧代等; R c是氢,取代或未取代的烷基等; R f为 - (CR 4a R 4b)n -R 2; R 4a和R 4b是氢,取代或未取代的烷基等; R 2是取代或未取代的环烷基等; n为1〜4的整数。 -R g为-X-R 3; -X-是-O-,-S-等; R 3为取代或未取代的环烷基等,或其药学上可接受的盐或溶剂合物。
摘要:
The present invention provides novel compounds having a P2X 3 and/or P2X 2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X 3 and/or P2X 2/3 receptor antagonistic effect comprising a compound of the formula (I):
wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; -X- is -N(R 16 )- or the like; R 16 is hydrogen, substituted or unsubstituted alkyl or the like; R 7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q 1 and Q 2 are each independently a carbon atom or a nitrogen atom; -L- is -O-, -S- or the like; R 6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R 2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.
摘要:
The present invention provides a novel P2X 3 and/or P2X 2 / 3 receptor antago nist. A compound represented by the formula (I):
wherein R a , R b and R c are, (a) R a and R b are taken together =Z; and R c is a group represented by R 1c ; or (b) R b and R c are taken together to form a bond; and R a is a group represented by -Y-R 1a ; R 1a and R 1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R 2 and R 3 are each independently substituted or unsubstituted aryl, etc.; R 4a and R 4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is -N(R 5 )-, etc.; R 5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; -Y- is -O-, etc.; =Z is =O, etc.; and n is an integer of 0 to 4.
摘要:
The present invention provides a novel P2X 3 and/or P2X 2 / 3 receptor antago nist. A compound represented by the formula (I):
wherein Z 1 is optionally protected hydroxy, etc.; Z 2 is -C(=O)-, etc.; Z 3a and Z 3b are taken together =O or =S; t is an integer of 0 to 4; R 4a and R 4b are each independently, hydrogen or substituted or unsubstituted lower alkyl, etc.; m and n are each independently an integer of 0 to 2; k is an integer of 0 or 1; Ring A is an aromatic carbocyclic ring or a heterocyclic ring, etc.; B is aromatic carbocyclic ring-diyl or heterocyclic ring-diyl, etc.; R 1a and R 1b are each independently halogen, hydroxy, substituted or unsubstituted lower alkyl, etc.; R 2 is substituted or unsubstituted alkyl, etc. R 3 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; or its pharmaceutically acceptable salt, or a solvate thereof is provided.
摘要翻译:本发明提供了新的P2X 3和/或P2X 2/3受体拮抗剂。 由式(I)表示的化合物:其中Z 1任选被保护的羟基等; Z 2是-C(= O) - 等; Z 3a和Z 3b合在一起= O或= S; t为0〜4的整数; R 4a和R 4b各自独立地为氢或取代或未取代的低级烷基等; m和n各自独立地为0〜2的整数; k是0或1的整数; 环A是芳族碳环或杂环等; B是芳族碳环环 - 二基或杂环环二基等; R 1a和R 1b各自独立地为卤素,羟基,取代或未取代的低级烷基等; R 2是取代或未取代的烷基等。R 3是取代或未取代的烷基,取代或未取代的芳基或取代或未取代的杂环基等; 或其药学上可接受的盐或其溶剂合物。